Leading into the Future

The past few years at Boston Scientific have shown the strength and resolve of our organization. And while numerous technologies have fueled our growth over that time, the anticipated 2003 U.S. launch of our paclitaxel-eluting stent is our primary focus.

Coronary stents have improved the lives of millions of patients since their introduction more than a decade ago. Today, this market is approximately $2.2 billion. Analysts believe that given the dramatic benefits of drug-eluting stents, it could grow to $5 billion or more in only a few years. In fact, the ability of drug-eluting stents to reduce restenosis rates has become so evident that Medicare reimbursement has already been approved in the United States.